Suppressor of Cytokine Signaling (SOCS) 5 Utilises Distinct Domains for Regulation of JAK1 and Interaction with the Adaptor Protein Shc-1

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Linossi, Edmond M ^a,b   Chandrashekaran, Indu R ^c   Kolesnik, Tatiana B ^a,b   Murphy, James M ^a,b   Webb, Andrew I ^a,b   Willson, Tracy A ^a,b   Kedzierski, Lukasz ^a,b   Bullock, Alex N ^d   Babon, Jeffrey J ^a,b   Norton, Raymond S ^c   Nicola, Nicos A ^a,b   Nicholson, Sandra E ^a,b  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c MONASH UNIVERSITY   (Australia)

^d UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; PROTEIN KINASE TYK2; PROTEIN SHC; PROTEIN SHC 1; SUPPRESSOR OF CYTOKINE SIGNALING; SUPPRESSOR OF CYTOKINE SIGNALING 1; SUPPRESSOR OF CYTOKINE SIGNALING 3; SUPPRESSOR OF CYTOKINE SIGNALING 5; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; AUTOPHOSPHORYLATION; BINDING AFFINITY; BINDING SITE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENETIC CONSERVATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION;

ANIMALS; BINDING SITES; CYTOKINES; GENETIC VECTORS; HEK293 CELLS; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; JANUS KINASE 1; JANUS KINASE 2; JANUS KINASE 3; MICE; PHOSPHOPEPTIDES; PHOSPHORYLATION; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SHC SIGNALING ADAPTOR PROTEINS; SIGNAL TRANSDUCTION; SRC HOMOLOGY DOMAINS; SUBSTRATE SPECIFICITY; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; SURFACE PLASMON RESONANCE; TYK2 KINASE;

EID: 84882636552     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0070536     Document Type: Article

References (64)

1. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
2. Gan HK, Burgess AW, Clayton AH, Scott AM, (2012) Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res 72: 2924-2930.
3. Pines G, Kostler WJ, Yarden Y, (2010) Oncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapy. FEBS Lett 584: 2699-2706.
4. Mullighan CG, (2012) The molecular genetic makeup of acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2012: 389-396.
5. Zhang J, Ding L, Holmfeldt L, Wu G, Heatley SL, et al. (2012) The genetic basis of early T-cell precursor acute lymphoblastic leukaemia. Nature 481: 157-163.
6. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, et al. (2005) Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 7: 387-397.
7. Kario E, Marmor MD, Adamsky K, Citri A, Amit I, et al. (2005) Suppressors of cytokine signaling 4 and 5 regulate epidermal growth factor receptor signaling. J Biol Chem 280: 7038-7048.
8. Nicholson SE, Metcalf D, Sprigg NS, Columbus R, Walker F, et al. (2005) Suppressor of cytokine signaling (SOCS)-5 is a potential negative regulator of epidermal growth factor signaling. Proc Natl Acad Sci U S A 102: 2328-2333.
9. Calvisi DF, Ladu S, Gorden A, Farina M, Lee JS, et al. (2007) Mechanistic and prognostic significance of aberrant methylation in the molecular pathogenesis of human hepatocellular carcinoma. J Clin Invest 117: 2713-2722.
10. Zhuang G, Wu X, Jiang Z, Kasman I, Yao J, et al. (2012) Tumour-secreted miR-9 promotes endothelial cell migration and angiogenesis by activating the JAK-STAT pathway. Embo J.
11. Callus BA, Mathey-Prevot B, (2002) SOCS36E, a novel Drosophila SOCS protein, suppresses JAK/STAT and EGF-R signalling in the imaginal wing disc. Oncogene 21: 4812-4821.
12. Rawlings JS, Rennebeck G, Harrison SM, Xi R, Harrison DA, (2004) Two Drosophila suppressors of cytokine signaling (SOCS) differentially regulate JAK and EGFR pathway activities. BMC Cell Biol 5: 38.
13. Zenatti PP, Ribeiro D, Li W, Zuurbier L, Silva MC, et al. (2011) Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia. Nat Genet 43: 932-939.
14. Endo TA, Masuhara M, Yokouchi M, Suzuki R, Sakamoto H, et al. (1997) A new protein containing an SH2 domain that inhibits JAK kinases. Nature 387: 921-924.
15. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, et al. (1997) A family of cytokine-inducible inhibitors of signalling. Nature 387: 917-921.
16. Naka T, Narazaki M, Hirata M, Matsumoto T, Minamoto S, et al. (1997) Structure and function of a new STAT-induced STAT inhibitor. Nature 387: 924-929.
17. Croker BA, Kiu H, Nicholson SE (2008) SOCS regulation of the JAK/STAT signalling pathway. Semin Cell Dev Biol.
18. Hilton DJ, Richardson RT, Alexander WS, Viney EM, Willson TA, et al. (1998) Twenty proteins containing a C-terminal SOCS box form five structural classes. Proc Natl Acad Sci U S A 95: 114-119.
19. Zhang JG, Farley A, Nicholson SE, Willson TA, Zugaro LM, et al. (1999) The conserved SOCS box motif in suppressors of cytokine signaling binds to elongins B and C and may couple bound proteins to proteasomal degradation. Proc Natl Acad Sci U S A 96: 2071-2076.
20. Ram PA, Waxman DJ, (2000) Role of the cytokine-inducible SH2 protein CIS in desensitization of STAT5b signaling by continuous growth hormone. J Biol Chem 275: 39487-39496.
21. Ram PA, Waxman DJ, (1999) SOCS/CIS protein inhibition of growth hormone-stimulated STAT5 signaling by multiple mechanisms. J Biol Chem 274: 35553-35561.
22. Matsumoto A, Masuhara M, Mitsui K, Yokouchi M, Ohtsubo M, et al. (1997) CIS, a cytokine inducible SH2 protein, is a target of the JAK-STAT5 pathway and modulates STAT5 activation. Blood 89: 3148-3154.
23. Greenhalgh CJ, Bertolino P, Asa SL, Metcalf D, Corbin JE, et al. (2002) Growth enhancement in suppressor of cytokine signaling 2 (SOCS-2)-deficient mice is dependent on signal transducer and activator of transcription 5b (STAT5b). Mol Endocrinol 16: 1394-1406.
24. Yasukawa H, Misawa H, Sakamoto H, Masuhara M, Sasaki A, et al. (1999) The JAK-binding protein JAB inhibits Janus tyrosine kinase activity through binding in the activation loop. Embo J 18: 1309-1320.
25. Sasaki A, Yasukawa H, Suzuki A, Kamizono S, Syoda T, et al. (1999) Cytokine-inducible SH2 protein-3 (CIS3/SOCS3) inhibits Janus tyrosine kinase by binding through the N-terminal kinase inhibitory region as well as SH2 domain. Genes Cells 4: 339-351.
26. Babon JJ, Kershaw NJ, Murphy JM, Varghese LN, Laktyushin A, et al. (2012) SOCS3 binds to a site unique to JAKs and inhibits their kinase activity via a novel, non-competitive mechanism. Immunity 36: 239-250.
27. Kershaw NJ, Murphy JM, Liau NPD, Varghese LN, Laktyushin A, et al. (2013) SOCS3 binds specific receptor-JAK complexes to control cytokine signaling by direct kinase inhibition. Nat Struct Mol Biol 20: 469-476.
28. Fenner JE, Starr R, Cornish AL, Zhang JG, Metcalf D, et al. (2006) Suppressor of cytokine signaling 1 regulates the immune response to infection by a unique inhibition of type I interferon activity. Nat Immunol 7: 33-39.
29. Qing Y, Costa-Pereira AP, Watling D, Stark GR, (2005) Role of tyrosine 441 of interferon-gamma receptor subunit 1 in SOCS-1-mediated attenuation of STAT1 activation. J Biol Chem 280: 1849-1853.
30. Feng ZP, Chandrashekaran IR, Low A, Speed TP, Nicholson SE, et al. (2012) The N-terminal domains of SOCS proteins: a conserved region in the disordered N-termini of SOCS4 and 5. Proteins 80: 946-957.
31. Choi YB, Son M, Park M, Shin J, Yun Y, (2010) SOCS-6 negatively regulates T cell activation through targeting p56lck to proteasomal degradation. J Biol Chem 285: 7271-7280.
32. Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, et al. (2002) Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci U S A 99: 13003-13008.
33. Brender C, Columbus R, Metcalf D, Handman E, Starr R, et al. (2004) SOCS5 is expressed in primary B and T lymphoid cells but is dispensable for lymphocyte production and function. Mol Cell Biol 24: 6094-6103.
34. Pardanani A, Gotlib JR, Jamieson C, Cortes JE, Talpaz M, et al. (2011) Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis. J Clin Oncol 29: 789-796.
35. Verstovsek S, Kantarjian H, Mesa RA, Pardanani AD, Cortes-Franco J, et al. (2010) Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis. N Engl J Med 363: 1117-1127.
36. Mizushima S, Nagata S, (1990) pEF-BOS, a powerful mammalian expression vector. Nucleic Acids Res 18: 5322.
37. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR, (1989) Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77: 61-68.
38. Bullock AN, Rodriguez MC, Debreczeni JE, Songyang Z, Knapp S, (2007) Structure of the SOCS4-ElonginB/C complex reveals a distinct SOCS box interface and the molecular basis for SOCS-dependent EGFR degradation. Structure 15: 1493-1504.
39. Babon JJ, McManus E, Yao S, DeSouza DP, Willson TA, et al. (2006) Structure of mouse SOCS3 reveals the structural basis of the extended SH2 domain function and identifies an unstructured insertion that regulates in vivo stability. Mol Cell 22: 205-216.
40. Babon JJ, Yao S, DeSouza DP, Harrison CF, Fabri LJ, et al. (2005) Secondary structure assignment of mouse SOCS3 by NMR defines the domain boundaries and identifies an unstructured insertion in the SH2 domain. FEBS J 272: 6120-6130.
41. Lucet IS, Fantino E, Styles M, Bamert R, Patel O, et al. (2006) The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor. Blood 107: 176-183.
42. Babon JJ, Murphy JM (2013) In Vitro JAK Kinase Activity and Inhibition Assays. In: Nicholson SE, Nicola NA, editors. JAK-STAT Signalling Methods and Protocols: Humana Press, USA. 39-56.
43. Lucet IS, Bamert R. (2013) Production and Crystallization of Recombinant JAK Proteins. In: Nicholson SE, Nicola NA, editors. JAK-STAT Signalling Methods and Protocols: Human Press, USA. 273-298.
44. Seeliger MA, Young M, Henderson MN, Pellicena P, King DS, et al. (2005) High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci 14: 3135-3139.
45. DuBridge RB, Tang P, Hsia HC, Leong PM, Miller JH, et al. (1987) Analysis of mutation in human cells by using an Epstein-Barr virus shuttle system. Mol Cell Biol 7: 379-387.
46. Lu B, Reichel M, Fisher DA, Smith JF, Rothman P, (1997) Identification of a STAT6 domain required for IL-4-induced activation of transcription. J Immunol 159: 1255-1264.
47. Nicholson SE, Novak U, Ziegler SF, Layton JE, (1995) Distinct regions of the granulocyte colony-stimulating factor receptor are required for tyrosine phosphorylation of the signaling molecules JAK2, Stat3, and p42, p44MAPK. Blood 86: 3698-3704.
48. Nicholson SE, Oates AC, Harpur AG, Ziemiecki A, Wilks AF, et al. (1994) Tyrosine kinase JAK1 is associated with the granulocyte-colony- stimulating factor receptor and both become tyrosine-phosphorylated after receptor activation. Proc Natl Acad Sci U S A 91: 2985-2988.
49. Li Z, Xing S, Wang S, Ho WT, Zhao ZJ, (2007) Characterization of a highly effective protein substrate for analysis of JAK2(V617F) Activity. Exp Hematol 35: 1624-1632.
50. Nicholson SE, Willson TA, Farley A, Starr R, Zhang JG, et al. (1999) Mutational analyses of the SOCS proteins suggest a dual domain requirement but distinct mechanisms for inhibition of LIF and IL-6 signal transduction. EMBO J 18: 375-385.
51. Nicholson SE, De Souza D, Fabri LJ, Corbin J, Willson TA, et al. (2000) Suppressor of cytokine signaling-3 preferentially binds to the SHP-2- binding site on the shared cytokine receptor subunit gp130. Proc Natl Acad Sci U S A 97: 6493-6498.
52. Pelicci G, Lanfrancone L, Grignani F, McGlade J, Cavallo F, et al. (1992) A novel transforming protein (SHC) with an SH2 domain is implicated in mitogenic signal transduction. Cell 70: 93-104.
53. Salcini AE, McGlade J, Pelicci G, Nicoletti I, Pawson T, et al. (1994) Formation of Shc-Grb2 complexes is necessary to induce neoplastic transformation by overexpression of Shc proteins. Oncogene 9: 2827-2836.
54. Rozakis-Adcock M, McGlade J, Mbamalu G, Pelicci G, Daly R, et al. (1992) Association of the Shc and Grb2/Sem5 SH2-containing proteins is implicated in activation of the Ras pathway by tyrosine kinases. Nature 360: 689-692.
55. van der Geer P, Wiley S, Gish GD, Pawson T, (1996) The Shc adaptor protein is highly phosphorylated at conserved, twin tyrosine residues (Y239/240) that mediate protein-protein interactions. Curr Biol 6: 1435-1444.
56. Bullock AN, Debreczeni JE, Edwards AM, Sundstrom M, Knapp S, (2006) Crystal structure of the SOCS2-elongin C-elongin B complex defines a prototypical SOCS box ubiquitin ligase. Proc Natl Acad Sci U S A 103: 7637-7642.
57. Ogura K, Tsuchiya S, Terasawa H, Yuzawa S, Hatanaka H, et al. (1999) Solution structure of the SH2 domain of Grb2 complexed with the Shc-derived phosphotyrosine-containing peptide. J Mol Biol 289: 439-445.
58. Batzer AG, Rotin D, Urena JM, Skolnik EY, Schlessinger J, (1994) Hierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor. Mol Cell Biol 14: 5192-5201.
59. Skolnik EY, Lee CH, Batzer A, Vicentini LM, Zhou M, et al. (1993) The SH2/SH3 domain-containing protein GRB2 interacts with tyrosine-phosphorylated IRS1 and Shc: implications for insulin control of ras signalling. EMBO J 12: 1929-1936.
60. Siddle K, (2011) Signalling by insulin and IGF receptors: supporting acts and new players. J Mol Endocrinol 47: R1-10.
61. Bolanos-Garcia VM, (2005) MET meet adaptors: functional and structural implications in downstream signalling mediated by the Met receptor. Mol Cell Biochem 276: 149-157.
62. Rohrschneider LR, Bourette RP, Lioubin MN, Algate PA, Myles GM, et al. (1997) Growth and differentiation signals regulated by the M-CSF receptor. Mol Reprod Dev 46: 96-103.
63. Ramshaw HS, Guthridge MA, Stomski FC, Barry EF, Ooms L, et al. (2007) The Shc-binding site of the betac subunit of the GM-CSF/IL-3/IL-5 receptors is a negative regulator of hematopoiesis. Blood 110: 3582-3590.
64. Zhang L, Camerini V, Bender TP, Ravichandran KS, (2002) A nonredundant role for the adapter protein Shc in thymic T cell development. Nat Immunol 3: 749-755.